Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

NCT06959082 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-11

No results posted yet for this study

Summary

This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.

Conditions

  • Head and Neck Cancer Squamous Cell Carcinoma

Interventions

DRUG

VS-101

VS-101

DRUG

Cisplatin

Cisplatin

RADIATION

Radiation

Radiation

Sponsors & Collaborators

  • VSPharmTech Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06959082 on ClinicalTrials.gov